CDC Mumps rRT-PCR Assay vs 2 for the Detection of Mumps Virus RNA in Clinical Samples

Details

• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  Version 3.0 08/20/21
  
  Changes compared to version 2: Version 2 listed incorrect cycling conditions. Version 3 lists the correct condition. The change is highlighted in green.
  
  This rRT-PCR assay is designed to detect both mumps vaccine and wild type strains. This assay targets the mumps N- gene. Version 1 of the assay (Rota et al., Clin. Vaccine Immunol. 20(3) 2013 p391) occasionally produced false-negative results with specimens in which the mumps forward primer and probe binding sites had nucleotide substitutions. The new version of the assay improves detection in these specimens through introduction of degenerate positions in the forward primer and probe. In addition, the enzyme mix was changed to the QuantiTect kit to allow use of the same enzyme that is used for the CDC measles and MeVA rRT-PCR assays. The reagents, instruments, and other information listed below have been validated by CDC for use in their CLIA-approved assays, but each laboratory should conduct their own validation and establish their own SOPs.
  
  
• Subjects:
  Molecular Diagnostic Techniques/methods Mumps/diagnosis Mumps Virus/classification Reverse Transcriptase Polymerase Chain Reaction/methods
• Document Type:
  Pamphlet (or booklet)
• Genre:
  Fact Sheet
• CIO:
  NCIRD
• Division:
  NCIRD_DVD
• Pages in Document:
  3 unnumbered pages
• Collection(s):
  Historical CDC.gov Content
• Main Document Checksum:
  urn:sha256:62e063324c696b9ae225eb34e9c6a4d500ea633b1972e3d9e61b0bb5fbb20211
• Download URL:
  https://stacks.cdc.gov/view/cdc/137327/cdc_137327_DS1.pdf
• File Type:
  [PDF - 156.04 KB ]